Urgent.News

What's breaking now, across thousands of outlets.

Health & Medicine

Mankind Pharma Q2 PAT rises 37.7% on strong domestic chronic business

The drugmaker's revenue rose 17.3 per cent to ₹4,338 crore in Q2 FY27, supported by strong demand for chronic therapies and growth in Bharat Serums and Vaccines' speciality portfolio.

Mankind Pharma Q2 PAT rises 37.7% on strong domestic chronic business

We haven't written up this one. Business Standard IN has the full story — the link below goes straight to it.

Read the original at business-standard.com →

More in Health & Medicine

Ebola: Border loopholes raise fears over Kenya’s preparedness

Amref Health Africa Group Chief Executive Officer Dr Githinji Gitahi has warned that gaps in border surveillance could expose Kenya to Ebola infections amid an outbreak in the neighbouring Democratic…

  • Dr. Githinji Gitahi warns weak border surveillance could expose Kenya to Ebola outbreak.
  • Contact tracing in DRC successful only 67%, leaving 32% of potential contacts unidentified.
  • Kenya's 42-day WHO-mandated monitoring period to confirm Ebola-free status.

More from Monday 26 October →